CN105985931A - NK cell in-vitro amplification composition and NK cell amplification method - Google Patents

NK cell in-vitro amplification composition and NK cell amplification method Download PDF

Info

Publication number
CN105985931A
CN105985931A CN201610451780.0A CN201610451780A CN105985931A CN 105985931 A CN105985931 A CN 105985931A CN 201610451780 A CN201610451780 A CN 201610451780A CN 105985931 A CN105985931 A CN 105985931A
Authority
CN
China
Prior art keywords
cell
culture medium
amplification
1bbl
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610451780.0A
Other languages
Chinese (zh)
Inventor
张怡
刘春香
芦慧颖
李琳
王浩宇
车彦川
刘艳青
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEILONGJIANG TIANQING STEM CELL Co Ltd
Original Assignee
HEILONGJIANG TIANQING STEM CELL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEILONGJIANG TIANQING STEM CELL Co Ltd filed Critical HEILONGJIANG TIANQING STEM CELL Co Ltd
Priority to CN201610451780.0A priority Critical patent/CN105985931A/en
Publication of CN105985931A publication Critical patent/CN105985931A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention discloses an NK cell in-vitro amplification composition and an NK cell amplification method and relates to an NK cell amplification composition and an amplification method. The invention aims at solving the problems of low multiple, low purity, long amplification period and high cost of current NK cell amplification. The composition comprises NK amplification trophocyte, IL-2, inactivated autologous plasma and GT-T551 H3 culture medium. The amplification method comprises the following steps: re-suspending PBMCs with the GT-T551 H3 culture medium; transferring into a culture bottle; adding the IL-2, NK amplification trophocyte and autologous plasma; and performing in-vitro co-culture for 15 days, wherein the NK amplification trophocyte is supplemented in the 7th day of the culture, the culture medium is supplemented in the culture process, and the cells are collected for detection in the 13th and 15th days of the culture. The composition can remarkably promote mass amplification of NK cells to meet the needs of clinical application; and the obtained NK cells have relatively high purity, the cost is saved, and the killing activity is improved. The NK cell in-vitro amplification composition and NK cell amplification method are applied to the amplification of NK cells.

Description

A kind of NK cell expansion ex vivo compositions and NK methods for cell expansion
Technical field
The present invention relates to a kind of NK cell amplification compositions and amplification method.
Background technology
The general status of 28 kinds of cancers of " report of world's cancer " of latest edition country individual to the whole world more than 180 and fashion trend Having carried out comprehensive description and analysis, address prediction whole world cases of cancer will present swift and violent growing trend, the whole world in 2012 Increase 14,000,000 cases of cancers altogether newly and have 8,200,000 people dead.Wherein, China increases 3,070,000 cancer patients newly and causes about 220 Ten thousand people are dead, account for the 21.9% and 26.8% of whole world total amount respectively.Wherein, pulmonary carcinoma, gastric cancer, hepatocarcinoma are that sickness rate is the highest Cancer, and breast carcinoma, colorectal cancer, cervical cancer make women's health be on the hazard.
Immunotherapy of tumors is known as the fourth-largest tumor therapy by domestic and international medical circle, wherein autoimmune cell (T cell, NK cell) treatment technology belongs to health ministry and allows the 3rd class medical skill of clinical practice in the first batch.In recent years, naturally kill Hinder cell (natural killer cell, NK) immunotherapy techniques and the most become a kind of reliable anticancer treatment Method, it is adaptable to clinical treatment and the side effect of Several Kinds of Malignancy are little, do not damage normal structure.NK was in 70 years 20th century In generation, enters the sight line of people, the so far developing history of existing nearly 40 years.NK cell is defined as large granular lymphocyte (LGL), it is to be differentiated by lymphoid progenitor cell, and constitutes three major types immunity carefully with bone-marrow-derived lymphocyte and T lymphocyte Born of the same parents, only account for the 5-10% of peripheral blood lymphocyte.NK cell can kill target cell (such as virus without contacting antigen in advance The host cell infected and tumor cell), owing to the killing activity of NK cell limits without MHC, because the most naturally killing Wound activity, it plays an important role during immune surveillance and early stage anti-infectious immunity.The tumor-killing mechanism bag of NK cell Include: (1) FasL Yu Fas phase separation, finally start target cell Apoptosis System.(2) perforin/granzyme effect, swashs Send out apoptosis relevant enzyme system and cause apoptosis.(3) the CD16 molecule of NK cell surface expression and tumour-specific IgG Antibody combines, thus identifies, kills the tumor cell specific binding with IgG antibody generation.(4)TNF-α、IFN-γ Deng the combination of receptor corresponding to target cells, start the Apoptosis System of target cell.NK cell is except target cell is had dissolving Outside lethal effect, NK cell also has critical function in organism immune response.NK cell can be by thin to M Ф, grain Born of the same parents, the regulation effect of dendritic cell and control natural immunity.NK cell can act on CD4+T cell and CD8+T Cell is to strengthen acquired immunity.
At present, external acquisition NK cells of human beings is mainly carried out by following approach: one, use the method for immunomagnetic beads from PBMC Middle separation；Two, the method stimulating amplification cultivation is used to expand NK cell from PBMC.The former can quickly obtain NK Cell, but a small amount of NK cell can only be obtained and study use altogether.The latter is then with PBMC as original material, passes through certain detail The stimulation of intracellular cytokine, makes NK cell obtain special amplification in vitro, is cultivated by external stimulation and can carry out relatively large rule Prepared by the NK cell of mould, thus be preferably applied for clinic.But existing in vitro method can only make NK cell in vitro Expand tens of to Radix Achyranthis Bidentatae, and CD3-CD56+ cell proportion is relatively low.The cytokines such as IL-2, IL-15, IL-18 and IL-21 Being very important to the growth of NK cell with amplification, meanwhile, 4-1BBL with NK cell surface receptor can be situated between after being combined The costimulatory signal led promotes NK cell proliferation, the secretion etc. of cytokine.Research confirms that the cytokines such as IL-2 are NK The essential condition of cell amplification, but only cytokine does not ensures that NK cell continues and efficient amplification, on a large scale The amplification of NK cell also needs to the support of more signaling system.K562 cell line is to suffer from from chronic granulocytic leukemia Extract the cell line set up in person's body, the amplification of NK cell can be activated.
At present, the main method of NK amplification is that the simple cell factor stimulates TRAP, and its amplification efficiency and purity are relatively low, with Time there is poor repeatability shortcoming.In recent years, occur that some stimulate with the trophocyte that have expressed IL-15 and 4-1BBL NK methods for cell expansion, the method expand 3 weeks after cell number up to 277 times, purity more than 90%, killing activity up to 80% (E:T=10:1).But needed for the NK cell quantity that this amplification method is cultivated needs the long period to can be only achieved clinical treatment Quantity, the most corresponding cost is the most of a relatively high.To sum up, existing NK cell injuring model method need to improve, simultaneously The most more be necessary to design the specification being consistent therewith reagent set incompatible guarantee cultural method timely, accurate, be smoothed out.
Summary of the invention
The present invention is to solve that current NK cells expanded is low, purity is low, amplification cycle length, problem that cost is high, carry For a kind of NK cell expansion ex vivo compositions and NK methods for cell expansion.
NK cell expansion ex vivo compositions of the present invention include NK amplification trophocyte, IL-2, the autologous plasma of inactivation and GT-T551 H3 culture medium.Every milliliter of GT-T551 H3 culture medium wherein adds 0.65 × 106Individual～1 × 106Individual NK expands Increase trophocyte, every milliliter of GT-T551 H3 culture medium adds the IL-2 of 200-500IU, the body of the autologous plasma of inactivation Amassing 5% for GT-T551 H3 culture volume, described NK amplification trophocyte is K562-4-1BBL-IL-15-IL-21 Trophocyte.
The present invention is by first the most frozen for the NK amplification trophocyte of inactivation, with when carry out recovery process again.
The preparation method of described K562-4-1BBL-IL-15-IL-21 trophocyte is:
A, utilize method for synthesizing gene, it is thus achieved that the full length coding region sequence of 4-1BBL-IL-15 fusion gene and IL-21 gene, Article two, upstream region of gene all adds CD8 alpha signal peptide, and downstream all adds CD8 α cross-film district；Meanwhile, on CD8 alpha signal peptide Trip introduces Nhe I restriction enzyme site, and CD8 α cross-film district introduces Not I restriction enzyme site.
B, build recombinant slow virus expression plasmid pCDH-CMV-MCS-4-1BBL-IL-15 and PCDH-CMV-MCS-IL-21:
Gene carrier pCDH-CMV-MCS-Vector and step A obtained is respectively with restricted enzyme Nhe I With Not I double digestion, 1% agarose gel reclaims after purification, is utilized respectively T4DNALigase and is attached, it is thus achieved that Connect product and be respectively designated as pCDH-CMV-MCS-4-1BBL-IL-15 and pCDH-CMV-MCS-IL-21, through enzyme action After identifying correctly ,-20 DEG C save backup.Wherein said pCDH-CMV-MCS-Vector buys the most biological lucky section from Shanghai Skill company limited, container name is pCDH-CMV-MCS-EF1-Puro (article No.: CD510B-1).
C, slow virus packaging:
A. dilute, with 235 μ L Opti-MEM, the connection product that 2.7 μ g steps B obtain PCDH-CMV-MCS-4-1BBL-IL-15, adds 1.76 μ g pLp1 (Gal/Pol), 0.95 μ g pLpVSVG and 0.68 μ g PLp2 (pREV), obtains a1 solution；The connection product that 2.7 μ g steps B obtain is diluted with 235 μ L Opti-MEM PCDH-CMV-MCS-IL-21, adds 1.76 μ g pLp1 (Gal/Pol), 0.95 μ g pLpVSVG and 0.68 μ g PLp2 (pREV), obtains a2 solution；
B. dilute 15 μ L lipofectamine2000 with 235 μ L Opti-MEM, obtain b solution；
C.5min, after, a1 solution, a2 solution are mixed with b solution respectively, is added drop-wise to respectively connect after the static 30min of room temperature Plant in 6 orifice plates of 293-T cell；
D.6-10h after, remove culture medium, add the DMED culture medium containing 10% (v/v) FBS, in 48h and 72h Each receive virus once, final obtain pCDH-CMV-MCS-4-1BBL-IL-15 slow virus and PCDH-CMV-MCS-IL-21 slow virus.
D., after two kinds of slow viruss of results being concentrated to 3E+8 TU/ml, virus mixes than 1:1 with titre, with 1000 MOI value carries out the infection of K562 cell line, and being cloned by flow cytometry and limiting dilution assay after infecting 72h can be steady The K562-4-1BBL-IL-15-IL-21 engineering cell of fixed heredity.
E. engineering cell strain is carried out 100Gy lonizing radiation and carry out lethal exposure, after irradiation, mix extraction 1 × 106Individual train Support, within every 2 days, calculate a Cell viability, find no survivaling cell after adding up 15 days and exist.
F. the K562-4-1BBL-IL-15-IL-21 engineering cell strain frozen stock solution of inactivation is carried out frozen, often pipe 1mL is dense Degree is 1 × 107Individual/mL, removes frozen stock solution with front 37 DEG C of recoveries.The formula of described frozen stock solution is 90% (v/v) FBS+10% (v/v)DMSO。
The method utilizing above-mentioned NK cell expansion ex vivo compositions to carry out NK cell amplification, sequentially includes the following steps:
By 30mL GT-T551 H3 culture medium by 2 × 107Individual～3 × 107After individual PBMCs is resuspended, accesses T75 cell and cultivate Bottle, IL-2, NK amplification trophocyte being subsequently adding and the autologous plasma of the inactivation accounting for culture volume 5%, the most often Milliliter GT-T551 H3 culture medium adds the IL-2 of 200-500IU, and every milliliter of GT-T551 H3 culture medium adds 0.65 × 106 Individual～1 × 106Individual NK expands trophocyte, in 37 DEG C of 5%CO2Under the conditions of co culture system in vitro 15 days, wherein cultivate the 7th It time add NK and expand trophocyte, before adding, the NK cell in culture fluid is counted, the NK added expands Increase the 1/5-1/4 that quantity is NK cell quantity of trophocyte.In incubation, NK cell observation is counted by every day, when NK cell density is more than 2.5 × 106/ mL must be supplemented with culture medium, and the culture medium added is for containing 200-500IU/mL IL-2 GT-T551 H3 culture medium, after fluid infusion, NK cell density maintains 0.8 × 106Individual/mL～1.0 × 106Individual/mL, cultivates Within 13 and 15 days, collect cell to detect.
Described NK amplification trophocyte is K562-4-1BBL-IL-15-IL-21 trophocyte.
Beneficial effects of the present invention:
(1) present invention is that the method being packed and infecting K562 cell by slow virus carries out 4-1BBL, IL-15, IL-21 The transduction of gene, the blood cell of suspension and tumor cell belong to difficult transfectional cell, and liposome transfection method effect is extremely low, and electricity is worn Hole method efficiency is higher, but relatively big to cell injury, and dead cell is very difficult to remove, the screening operation after impact transfection.Slow sick Poison infection method is a kind of a kind of gentleer to cell and that transfection efficiency is higher method, solves suspension cell transfection and is faced The problems referred to above.
(2) present invention first carries out selected by flow cytometry apoptosis with the purplish red element IL-21 antibody of labelling and IL-15 antibody, removes Negative K562 cell, then double positive cell groups of screening are carried out limiting dilution assay clone can stablize hereditary K562-4-1BBL-IL-15-IL-21 engineering cell, two kinds of methods combine and can shorten the screening cycle, make whole process 1 I.e. can complete within individual month, save R&D costs simultaneously.
(3) engineering cell strain is carried out 100Gy lonizing radiation and carries out lethal exposure by the present invention, mixes extraction 1 × 10 after irradiation6 Individual cultivating, within every 2 days, calculate a Cell viability, find no survivaling cell existence after add up 15 days, the method can To ensure the engineering cell strain safety for NK amplification.
(4) present invention uses autologous plasma to promote the propagation of cell, and exogenous factor only adds the IL-2 of relatively low-dose, keeps away Exempt from the probability of the pollution of extrinsic protein and virus, and greatly reduce production cost；
(5) NK cell culture compositions of the present invention can promote a large amount of propagation of NK cell, and purity is higher, can improve The killing activity of its cell.Its killing of interior tumor cell that can be not only used for tumor patient and immune regulation, Can apply to the health care of sub-health population simultaneously.
IL-21, while K562 surface of cell membrane expresses IL-15 Yu 4-1BBL, is expressed in K562 by the present invention the most simultaneously Cell surface, the most solvable state adds IL-2, IL-15 Yu IL-21 is combined by the present invention, the two synergism, significantly Improve invention effect.Said composition can remarkably promote a large amount of amplifications of NK cell, meets clinical practice demand, and K562 is thin Cellular expression is also embedded in the albumen on its surface NK cell aggregation can be made fully to be stimulated in its surface, it is thus achieved that NK Cell purity is higher, and the method it also avoid the probability of pollution of extrinsic protein and virus simultaneously, saves NK cell Preparation cost, and improve the killing activity of tumor cell.
Figure of description
Fig. 1 is the cell proliferation number change in test 1 amplification procedure；
Cell purity when Fig. 2 is that in test 1, experimental group is cultivated 13 days；
Cell purity when Fig. 3 is that in test 1, experimental group is cultivated 15 days；
Cell purity when Fig. 4 is that in test 1, matched group 1 is cultivated 13 days；
Cell purity when Fig. 5 is that in test 1, matched group 1 is cultivated 15 days；
Cell purity when Fig. 6 is that in test 1, matched group 2 is cultivated 13 days；
Cell purity when Fig. 7 is that in test 1, matched group 2 is cultivated 15 days；
Fig. 8 is the killing activity contrast after test 1 is cultivated 15 days to NK cell A549.
Detailed description of the invention
Technical solution of the present invention is not limited to act detailed description of the invention set forth below, also includes appointing between each detailed description of the invention Meaning combination.
Detailed description of the invention one: present embodiment NK cell expansion ex vivo compositions include NK amplification trophocyte, IL-2, The autologous plasma of inactivation and GT-T551 H3 culture medium, wherein add 0.65 × 10 in every milliliter of GT-T551 H3 culture medium6 Individual～1 × 106Individual NK expands trophocyte, adds the IL-2 of 200-500IU, go out in every milliliter of GT-T551 H3 culture medium Volume is GT-T551 H3 culture volume the 5% of the autologous plasma lived, described NK amplification trophocyte is K562-4-1BBL-IL-15-IL-21 trophocyte.
The factor promoting NK cell activation propagation is mainly embedded in this by the amplification in vitro method of NK cell of the present invention Body has the K562 cell surface of inducing action to NK cell, makes NK cell can preferably activate and expand so that it is There is the killing activity of more preferable tumor cell；The method takes a short time, and safety is high, can apply to clinical cytology raw Thing is treated, including renal carcinoma, malignant melanoma, leukemia, breast carcinoma, rectal cancer, gastric cancer, pulmonary carcinoma, the esophageal carcinoma, palace The malignancy diseases such as neck cancer, ovarian cancer, multiple myeloma, malignant lymphoma (non-T cell lymphoma), especially Can apply to immune system research and the research of tumor-killing effect.
Detailed description of the invention two: present embodiment is unlike detailed description of the invention one: every milliliter of GT-T551 H3 cultivates Base adds 0.7 × 106Individual～0.9 × 106Individual NK expands trophocyte.Other is identical with detailed description of the invention one.
Detailed description of the invention three: present embodiment is unlike detailed description of the invention one or two: every milliliter of GT-T551 H3 Culture medium adds 0.8 × 106Individual NK expands trophocyte.Other is identical with detailed description of the invention one or two.
Detailed description of the invention four: present embodiment is unlike one of detailed description of the invention one to three: every milliliter of GT-T551 H3 culture medium adds the IL-2 of 300-400IU.Other is identical with one of detailed description of the invention one to three.
Detailed description of the invention five: present embodiment is unlike one of detailed description of the invention one to three: every milliliter of GT-T551 H3 culture medium adds the IL-2 of 350IU.Other is identical with one of detailed description of the invention one to three.
Detailed description of the invention six: present embodiment is unlike one of detailed description of the invention one to five: described The preparation method of K562-4-1BBL-IL-15-IL-21 trophocyte is:
A, utilize method for synthesizing gene, it is thus achieved that the fusion gene 4-1BBL-IL-15 of 4-1BBL gene and IL-15 gene and The full length coding region sequence of IL-21 gene, two upstream region of gene all add CD8 alpha signal peptide, and downstream all adds CD8 α cross-film District；Meanwhile, CD8 alpha signal peptide upstream introduces Nhe I restriction enzyme site, and CD8 α cross-film district introduces Not I restriction enzyme site；
B, build recombinant slow virus expression plasmid pCDH-CMV-MCS-4-1BBL-IL-15 and PCDH-CMV-MCS-IL-21:
Gene pCDH-CMV-MCS-Vector and step A obtained is respectively with restricted enzyme Nhe I and Not I double digestion, 1% agarose gel reclaim after purification, be utilized respectively T4DNALigase and be attached, it is thus achieved that connection Product is respectively designated as pCDH-CMV-MCS-4-1BBL-IL-15 and pCDH-CMV-MCS-IL-21, identifies through enzyme action After Zheng Que ,-20 DEG C save backup；
C, slow virus packaging:
A. dilute, with 235 μ L Opti-MEM, the connection product that 2.7 μ g steps B obtain PCDH-CMV-MCS-4-1BBL-IL-15, adds 1.76 μ g pLp1 (Gal/Pol), 0.95 μ g pLpVSVG and 0.68 μ g PLp2 (pREV), obtains a1 solution；The connection product that 2.7 μ g steps B obtain is diluted with 235 μ L Opti-MEM PCDH-CMV-MCS-IL-21, adds 1.76 μ g pLp1 (Gal/Pol), 0.95 μ g pLpVSVG and 0.68 μ g PLp2 (pREV), obtains a2 solution；
B. dilute 15 μ L lipofectamine2000 with 235 μ L Opti-MEM, obtain b solution；
C.5min, after, a1 solution, a2 solution are mixed with b solution respectively, is added drop-wise to respectively connect after the static 30min of room temperature Plant in 6 orifice plates of 293-T cell；
D.6-10h after, remove culture medium, add the DMED culture medium containing 10% (v/v) FBS, in 48h and 72h Each receive virus once, final obtain pCDH-CMV-MCS-4-1BBL-IL-15 slow virus and PCDH-CMV-MCS-IL-21 slow virus.
D., after two kinds of slow viruss of results being concentrated to 3E+8 TU/ml, virus mixes than 1:1 with titre, with 1000 MOI value carries out the infection of K562 cell line, and being cloned by flow cytometry and limiting dilution assay after infecting 72h can be steady The K562-4-1BBL-IL-15-IL-21 engineering cell of fixed heredity.
E. engineering cell strain is carried out 100Gy lonizing radiation and carry out lethal exposure, after irradiation, mix extraction 1 × 106Individual train Support, within every 2 days, calculate a Cell viability, find no survivaling cell after adding up 15 days and exist.
F. the K562-4-1BBL-IL-15-IL-21 engineering cell strain frozen stock solution of inactivation is carried out frozen, often pipe 1mL is dense Degree is 1 × 107Individual/mL, removes frozen stock solution with front 37 DEG C of recoveries.Other is identical with one of detailed description of the invention one to five.
Detailed description of the invention seven: present embodiment is unlike detailed description of the invention six: the formula of described frozen stock solution is 90% (v/v) FBS+10% (v/v) DMSO.Other is identical with detailed description of the invention six.
Detailed description of the invention eight: present embodiment NK methods for cell expansion, sequentially includes the following steps:
By 30mL GT-T551 H3 culture medium by 2 × 107Individual～3 × 107After individual PBMCs is resuspended, accesses T75 cell and cultivate Bottle, IL-2, NK amplification trophocyte being subsequently adding and the autologous plasma of the inactivation accounting for culture volume 5%, the most often Milliliter GT-T551 H3 culture medium adds the IL-2 of 200-500IU, and every milliliter of GT-T551 H3 culture medium adds 0.65 × 106 Individual～1 × 106Individual NK expands trophocyte, in 37 DEG C of 5%CO2Under the conditions of co culture system in vitro 15 days, wherein cultivate the 7th It time add NK and expand trophocyte, before adding, the NK cell in culture fluid is counted, the NK added expands Increase the 1/5-1/4 that quantity is NK cell quantity of trophocyte.In incubation, NK cell observation is counted by every day, when NK cell density is more than 2.5 × 106/ mL must be supplemented with culture medium, and the culture medium added is for containing 200-500IU/mL IL-2 GT-T551 H3 culture medium, after fluid infusion, NK cell density maintains 0.8 × 106Individual/mL～1.0 × 106Individual/mL, cultivates Within 13 and 15 days, collect cell to detect.
Detailed description of the invention nine: present embodiment is unlike detailed description of the invention eight: train with 30mL GT-T551 H3 Support base by 2.5 × 107Individual PBMCs is resuspended.Other is identical with detailed description of the invention eight.
Detailed description of the invention ten: present embodiment is unlike detailed description of the invention eight: every milliliter of GT-T551 H3 cultivates Base adds the IL-2 of 300-400IU.Other is identical with detailed description of the invention eight.
Detailed description of the invention ten: present embodiment is unlike detailed description of the invention eight: every milliliter of GT-T551 H3 cultivates Base adds the IL-2 of 240IU.Other is identical with detailed description of the invention eight.
Detailed description of the invention 11: present embodiment is unlike detailed description of the invention eight: every milliliter of GT-T551 H3 training Support base and add 0.7 × 106Individual～0.9 × 106Individual NK expands trophocyte.Other is identical with detailed description of the invention eight.
Detailed description of the invention 12: present embodiment is unlike detailed description of the invention eight: every milliliter of GT-T551 H3 training Support base and add 0.8 × 106Individual NK expands trophocyte.Other is identical with detailed description of the invention eight.
Detailed description of the invention 13: present embodiment is unlike detailed description of the invention eight: described NK expands trophocyte For K562-4-1BBL-IL-15-IL-21 trophocyte, the acquisition of described K562-4-1BBL-IL-15-IL-21 trophocyte Method is:
A, utilize method for synthesizing gene, it is thus achieved that the fusion gene 4-1BBL-IL-15 of 4-1BBL gene and IL-15 gene and The full length coding region sequence of IL-21 gene, two upstream region of gene all add CD8 alpha signal peptide, and downstream all adds CD8 α cross-film District；Meanwhile, CD8 alpha signal peptide upstream introduces Nhe I restriction enzyme site, and CD8 α cross-film district introduces Not I restriction enzyme site；
B, build recombinant slow virus expression plasmid pCDH-CMV-MCS-4-1BBL-IL-15 and PCDH-CMV-MCS-IL-21:
Gene pCDH-CMV-MCS-Vector and step A obtained is respectively with restricted enzyme Nhe I and Not I double digestion, 1% agarose gel reclaim after purification, be utilized respectively T4DNALigase and be attached, it is thus achieved that connection Product is respectively designated as pCDH-CMV-MCS-4-1BBL-IL-15 and pCDH-CMV-MCS-IL-21, identifies through enzyme action After Zheng Que ,-20 DEG C save backup；
C, slow virus packaging:
A. dilute, with 235 μ L Opti-MEM, the connection product that 2.7 μ g steps B obtain PCDH-CMV-MCS-4-1BBL-IL-15, adds 1.76 μ g pLp1 (Gal/Pol), 0.95 μ g pLpVSVG and 0.68 μ g PLp2 (pREV), obtains a1 solution；The connection product that 2.7 μ g steps B obtain is diluted with 235 μ L Opti-MEM PCDH-CMV-MCS-IL-21, adds 1.76 μ g pLp1 (Gal/Pol), 0.95 μ g pLpVSVG and 0.68 μ g PLp2 (pREV), obtains a2 solution；
B. dilute 15 μ L lipofectamine2000 with 235 μ L Opti-MEM, obtain b solution；
C.5min, after, a1 solution, a2 solution are mixed with b solution respectively, is added drop-wise to respectively connect after the static 30min of room temperature Plant in 6 orifice plates of 293-T cell；
D.6-10h after, remove culture medium, add the DMED culture medium containing 10% (v/v) FBS, in 48h and 72h Each receive virus once, final obtain pCDH-CMV-MCS-4-1BBL-IL-15 slow virus and PCDH-CMV-MCS-IL-21 slow virus.
D., after two kinds of slow viruss of results being concentrated to 3E+8 TU/ml, virus mixes than 1:1 with titre, with 1000 MOI value carries out the infection of K562 cell line, and being cloned by flow cytometry and limiting dilution assay after infecting 72h can be steady The K562-4-1BBL-IL-15-IL-21 engineering cell of fixed heredity.
E. engineering cell strain is carried out 100Gy lonizing radiation and carry out lethal exposure, after irradiation, mix extraction 1 × 106Individual train Support, within every 2 days, calculate a Cell viability, find no survivaling cell after adding up 15 days and exist.
F. the K562-4-1BBL-IL-15-IL-21 engineering cell strain frozen stock solution of inactivation is carried out frozen, often pipe 1mL is dense Degree is 1 × 107Individual/mL, goes frozen stock solution, the formula of described frozen stock solution to be 90% (v/v) FBS+10% with front 37 DEG C of recoveries (v/v)DMSO.Other is identical with detailed description of the invention eight.
For checking beneficial effects of the present invention, carry out tests below:
Test 1: this test NK cell expansion ex vivo compositions and NK methods for cell expansion
One, preparation K562-4-1BBL-IL-15-IL-21 trophocyte
A, utilize method for synthesizing gene, it is thus achieved that the fusion gene 4-1BBL-IL-15 of 4-1BBL gene and IL-15 gene, The fusion gene 4-1BBL-IL-21 of 4-1BBL gene and IL-21 gene and the full length coding region sequence of IL-21 gene, two Bar upstream region of gene all adds CD8 alpha signal peptide, and downstream all adds CD8 α cross-film district；Meanwhile, CD8 alpha signal peptide upstream Introducing Nhe I restriction enzyme site, CD8 α cross-film district introduces Not I restriction enzyme site；
B, build recombinant slow virus expression plasmid pCDH-CMV-MCS-4-1BBL-IL-15, PCDH-CMV-MCS-4-1BBL-IL-21 and pCDH-CMV-MCS-IL-21:
Gene pCDH-CMV-MCS-Vector and step A obtained is respectively with restricted enzyme Nhe I and Not I double digestion, 1% agarose gel reclaim after purification, be utilized respectively T4DNALigase and be attached, it is thus achieved that connection Product be respectively designated as pCDH-CMV-MCS-4-1BBL-IL-15, pCDH-CMV-MCS-4-1BBL-IL-21 and PCDH-CMV-MCS-IL-21, after enzyme action is identified correctly ,-20 DEG C save backup；
C, slow virus packaging:
A. dilute, with 235 μ L Opti-MEM, the connection product that 2.7 μ g steps B obtain PCDH-CMV-MCS-4-1BBL-IL-15, adds 1.76 μ g pLp1 (Gal/Pol), 0.95 μ g pLpVSVG and 0.68 μ g PLp2 (pREV), obtains a1 solution；The connection product that 2.7 μ g steps B obtain is diluted with 235 μ L Opti-MEM PCDH-CMV-MCS-IL-21, adds 1.76 μ g pLp1 (Gal/Pol), 0.95 μ g pLpVSVG and 0.68 μ g PLp2 (pREV), obtains a2 solution；The connection product that 2.7 μ g steps B obtain is diluted with 235 μ L Opti-MEM PCDH-CMV-MCS-4-1BBL-IL-21, adds 1.76 μ g pLp1 (Gal/Pol), 0.95 μ g pLpVSVG and 0.68 μ g PLp2 (pREV), obtains a3 solution；
B. dilute 15 μ L lipofectamine2000 with 235 μ L Opti-MEM, obtain b solution；
C.5min, after, a1 solution, a2 solution, a3 solution are mixed with b solution respectively, after the static 30min of room temperature respectively It is added drop-wise in 6 orifice plates of inoculation 293-T cell；
D.6-10h after, remove culture medium, add the DMED culture medium containing 10% (v/v) FBS, in 48h and 72h Respectively receive virus once, final acquisition pCDH-CMV-MCS-4-1BBL-IL-15 slow virus, PCDH-CMV-MCS-4-1BBL-IL-21 slow virus and pCDH-CMV-MCS-IL-21 slow virus.
D. after two kinds of slow viruss of results are concentrated to 3E+8 TU/ml by experimental group, will PCDH-CMV-MCS-4-1BBL-IL-15 slow virus and pCDH-CMV-MCS-IL-21 slow virus compare 1:1 with titre Mixing, carries out the infection of K562 cell line with the MOI value of 1000, and matched group 1 will PCDH-CMV-MCS-4-1BBL-IL-15 slow virus carries out K562 cell infection, matched group 2 with the MOI value of 500 PCDH-CMV-MCS-4-1BBL-IL-21 slow virus is carried out K562 cell infection with the MOI value of 500, infects 72h Cloned by flow cytometry and limiting dilution assay afterwards can stablize heredity K562-4-1BBL-IL-15 (matched group 1), K562-4-1BBL-IL-21 (matched group 2) and K562-4-1BBL-IL-15-IL-21 (experimental group) engineering cell.
The present invention first carries out selected by flow cytometry apoptosis with the purplish red element IL-21 antibody of labelling and IL-15 antibody, removes feminine gender K562 cell, then double positive cell groups of screening are carried out limiting dilution assay clone can stablize hereditary K562-4-1BBL-IL-15-IL-21 engineering cell, two kinds of methods combine and can shorten the screening cycle, make whole process 1 I.e. can complete within individual month, save R&D costs simultaneously.
E. engineering cell strain is carried out 100Gy lonizing radiation and carry out lethal exposure, after irradiation, mix extraction 1 × 106Individual train Support, within every 2 days, calculate a Cell viability, find no survivaling cell after adding up 15 days and exist.
F. the K562-4-1BBL-IL-15-IL-21 engineering cell strain of inactivation is carried out frozen (frozen stock solution formula is 90%FBS+10%DMSO), every pipe 1 × 107Individual/ml, removes frozen stock solution with front 37 DEG C of recoveries.
Two, experimental group by 30mL GT-T551 H3 culture medium by 2 × 107Individual～3 × 107After individual PBMCs is resuspended, access T75 Tissue Culture Flask, IL-2, the NK being subsequently adding amplification trophocyte and account for inactivation autologous of culture volume 5% Blood plasma, the wherein IL-2 of every milliliter of GT-T551 H3 culture medium addition 200-500IU, every milliliter of GT-T551 H3 cultivates Base adds 0.65 × 106Individual～1 × 106Individual NK expands trophocyte, in 37 DEG C of 5%CO2Under the conditions of co culture system in vitro 15 days, Add a NK when wherein cultivating the 7th day and expand trophocyte, before adding, the NK cell in culture fluid is counted, Quantity is NK cell quantity the 1/4 of the NK amplification trophocyte added.In incubation, every day is to NK cell observation Counting, when NK cell density is more than 2.5 × 106/ mL must be supplemented with culture medium, and the culture medium added is for containing 240IU/mL The GT-T551 H3 culture medium of IL-2, after fluid infusion, NK cell density maintains 1.0 × 106Individual/mL, respectively at cultivating the 5th My god, 7 days, 9 days, 11 days, 13 and 15 days collect cell detect.
Matched group 1, matched group 2 are identical with the operation of experimental group, and simply trophocyte is replaced by by matched group 1 K562-4-1BBL-IL-15, trophocyte is replaced by K562-4-1BBL-IL-21 by matched group 2.
Testing result is as follows:
(1) the NK cell quantity (hundred million) expanded
The PBMCs quantity of each group initial inoculation is 3 × 107Cells, within i.e. the 0th day, cell number is 0.30 ± 0.00 hundred million
Table 1
Fig. 1 is the cell proliferation number change in amplification procedure, in Fig. 1 ● representing experimental group, ■ represents matched group 1, ▲ Represent matched group 2.During cell amplification 15d, experimental group cell quantity is 114.00 ± 12.37, and matched group 1 cell quantity is 68.4 ± 9.75, matched group 2 cell quantity is 59.6 ± 8.67.The cell quantity of experimental group amplification is significantly higher than matched group 1 And matched group 2 (P1=0.0037 < 0.01, P2=0.0034 < 0.01), the cell quantity of matched group 1 and matched group 2 amplification without Significant difference (P=0.1538 > 0.05), illustrates that 4-1BBL, IL-15 and IL-21 are expressed in cell surface simultaneously thin to NK The expanding effect of born of the same parents is better than containing only 4-1BBL, IL-15 or 4-1BBL, the effect of IL-21.
(2) motility rate, purity:
Table 2
Fig. 2 be experimental group cultivate 13 days time cell purity；Fig. 3 be experimental group cultivate 15 days time cell purity；Fig. 4 Cell purity when cultivating 13 days for matched group 1；Fig. 5 is the matched group 1 cell purity when cultivating 15 days；Fig. 6 is Matched group 2 cultivates cell purity when 13 days；Fig. 7 is the matched group 2 cell purity when cultivating 15 days.
As seen from the figure, in experimental group cell, CD3-, CD56+ ratio is significantly higher than experimental group 1 and experimental group 2, and matched group 1 and matched group 2 without significant difference, illustrate that 4-1BBL, IL-15 and IL-21 are expressed in cell surface simultaneously and more only express The amplification impurities affect effect of NK cell is become apparent from by 4-1BBL, IL-15 or 4-1BBL, IL-21.Each group cell expands Increasing 13 days and the CD3-of 15 days, the change of CD56+ cell purity is inconspicuous, illustrates that when 13 days, NK cell is the most ripe.
(3) the NK cell the gathered in the crops killing activity to A549 cell
A549 cell inoculum concentration is 10000cells/ hole, and effect target ratio for 10:1, observes NK cell constantly to A549 cell Fragmentation effect.Add NK cell when inoculating about 19h, about during 90h, reach maximum fragmentation effect, experimental group, matched group 1 and matched group 2NK killing-efficiency be respectively as follows: 90.64%, 82.61%, 73.33%.
Fig. 8 is to cultivate after 15 days the killing activity to NK cell A549 to contrast, and in Fig. 8, curve 1,2 represents blank right According to group (i.e. without immunocyte), curve 3,4 represents matched group 1, and curve 5,6 represents matched group 2, curve 7, 8 represent experimental group.A549 cell inoculum concentration is 10000cells/ hole, and effect target ratio for 10:1, observes NK cell pair constantly The fragmentation effect of A549 cell.Add NK cell when inoculating about 19h, about during 90h, reach maximum fragmentation effect, experiment Group, matched group 1 and matched group 2NK killing-efficiency average are respectively as follows: 90.64%, 82.61%, 73.33, and each group all has There is good tumors inhibition activity, and the tumor-killing effect of experimental group becomes apparent from.

Claims (10)

1. a NK cell expansion ex vivo compositions, it is characterised in that said composition include NK amplification trophocyte, IL-2, The autologous plasma of inactivation and GT-T551 H3 culture medium, wherein add 0.65 × 10 in every milliliter of GT-T551 H3 culture medium6Individual ～1 × 106Individual NK expands trophocyte, adds the IL-2 of 200-500IU in every milliliter of GT-T551 H3 culture medium, inactivation The volume of autologous plasma is the 5% of GT-T551 H3 culture volume, and described NK amplification trophocyte is K562-4-1BBL-IL-15-IL-21 trophocyte.
A kind of NK cell expansion ex vivo compositions the most according to claim 1, it is characterised in that every milliliter of GT-T551 H3 culture medium adds 0.7 × 106Individual～0.9 × 106Individual NK expands trophocyte.
A kind of NK cell expansion ex vivo compositions the most according to claim 1, it is characterised in that every milliliter of GT-T551 H3 culture medium adds 0.8 × 106Individual NK expands trophocyte.
A kind of NK cell expansion ex vivo compositions the most according to claim 1, it is characterised in that every milliliter of GT-T551 H3 culture medium adds the IL-2 of 300-400IU.
A kind of NK cell expansion ex vivo compositions the most according to claim 1, it is characterised in that every milliliter of GT-T551 H3 culture medium adds the IL-2 of 350IU.
A kind of NK cell expansion ex vivo compositions the most according to claim 1, it is characterised in that described The preparation method of K562-4-1BBL-IL-15-IL-21 trophocyte is:
A, utilize method for synthesizing gene, it is thus achieved that the fusion gene 4-1BBL-IL-15 of 4-1BBL gene and IL-15 gene and The full length coding region sequence of IL-21 gene, two upstream region of gene all add CD8 alpha signal peptide, and downstream all adds CD8 α cross-film District；Meanwhile, CD8 alpha signal peptide upstream introduces Nhe I restriction enzyme site, and CD8 α cross-film district introduces Not I restriction enzyme site；
B, build recombinant slow virus expression plasmid pCDH-CMV-MCS-4-1BBL-IL-15 and PCDH-CMV-MCS-IL-21:
Gene pCDH-CMV-MCS-Vector and step A obtained is respectively with restricted enzyme Nhe I and Not I Double digestion, 1% agarose gel reclaim after purification, be utilized respectively T4DNALigase and be attached, it is thus achieved that connection product It is respectively designated as pCDH-CMV-MCS-4-1BBL-IL-15 and pCDH-CMV-MCS-IL-21, identifies through enzyme action correct After ,-20 DEG C save backup；
C, slow virus packaging:
A. dilute, with 235 μ L Opti-MEM, the connection product that 2.7 μ g steps B obtain PCDH-CMV-MCS-4-1BBL-IL-15, adds 1.76 μ g pLp1,0.95 μ g pLpVSVG and 0.68 μ g pLp2, Obtain a1 solution；The connection product that 2.7 μ g steps B obtain is diluted with 235 μ L Opti-MEM PCDH-CMV-MCS-IL-21, adds 1.76 μ g pLp1,0.95 μ g pLpVSVG and 0.68 μ g pLp2, obtains a2 Solution；
B. dilute 15 μ L lipofectamine2000 with 235 μ L Opti-MEM, obtain b solution；
C.5min after, a1 solution, a2 solution are mixed with b solution respectively, after the static 30min of room temperature, be added drop-wise to inoculation respectively In 6 orifice plates of 293-T cell；
D.6-10h after, remove culture medium, add the DMED culture medium containing 10% (v/v) FBS, in 48h and 72h Each receive virus once, final obtain pCDH-CMV-MCS-4-1BBL-IL-15 slow virus and PCDH-CMV-MCS-IL-21 slow virus.
D., after two kinds of slow viruss of results being concentrated to 3E+8TU/ml, virus mixes than 1:1 with titre, with 1000 MOI value carries out the infection of K562 cell line, and being cloned by flow cytometry and limiting dilution assay after infecting 72h can be steady The K562-4-1BBL-IL-15-IL-21 engineering cell of fixed heredity.
E. engineering cell strain is carried out 100Gy lonizing radiation and carry out lethal exposure, after irradiation, mix extraction 1 × 106Individual train Support, within every 2 days, calculate a Cell viability, find no survivaling cell after adding up 15 days and exist.
F. the K562-4-1BBL-IL-15-IL-21 engineering cell strain frozen stock solution of inactivation is carried out frozen, often pipe 1mL, concentration It is 1 × 107Individual/mL, removes frozen stock solution with front 37 DEG C of recoveries.
A kind of NK cell expansion ex vivo compositions the most according to claim 6, it is characterised in that joining of described frozen stock solution Side is 90% (v/v) FBS+10% (v/v) DMSO.
8.NK methods for cell expansion, it is characterised in that the method sequentially includes the following steps:
By 30mL GT-T551 H3 culture medium by 2 × 107Individual～3 × 107After individual PBMCs is resuspended, accesses T75 cell and cultivate Bottle, IL-2, NK amplification trophocyte being subsequently adding and the autologous plasma of the inactivation accounting for culture volume 5%, wherein every milli Rising the IL-2 that GT-T551 H3 culture medium adds 200-500IU, every milliliter of GT-T551 H3 culture medium adds 0.65 × 106Individual ～1 × 106Individual NK expands trophocyte, in 37 DEG C of 5%CO2Under the conditions of co culture system in vitro 15 days, when wherein cultivating the 7th day Adding a NK and expand trophocyte, before adding count the NK cell in culture fluid, the NK amplification added is grown Supporting the 1/5-1/4 that quantity is NK cell quantity of cell, in incubation, NK cell observation is counted, when NK is thin by every day Born of the same parents' density is more than 2.5 × 106/ mL must be supplemented with culture medium, and the culture medium added is containing 200-500IU/mL IL-2's GT-T551 H3 culture medium, after fluid infusion, NK cell density maintains 0.8 × 106Individual/mL～1.0 × 106Individual/mL, cultivates 13 Hes Within 15 days, collect cell to detect.
NK methods for cell expansion the most according to claim 1, it is characterised in that by 30mL GT-T551 H3 culture medium By 2.5 × 107Individual PBMCs is resuspended.
NK methods for cell expansion the most according to claim 1, it is characterised in that every milliliter of GT-T551 H3 culture medium Add the IL-2 of 240IU.
CN201610451780.0A 2016-06-21 2016-06-21 NK cell in-vitro amplification composition and NK cell amplification method Pending CN105985931A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610451780.0A CN105985931A (en) 2016-06-21 2016-06-21 NK cell in-vitro amplification composition and NK cell amplification method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610451780.0A CN105985931A (en) 2016-06-21 2016-06-21 NK cell in-vitro amplification composition and NK cell amplification method

Publications (1)

Publication Number Publication Date
CN105985931A true CN105985931A (en) 2016-10-05

Family

ID=57043988

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610451780.0A Pending CN105985931A (en) 2016-06-21 2016-06-21 NK cell in-vitro amplification composition and NK cell amplification method

Country Status (1)

Country Link
CN (1) CN105985931A (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107354133A (en) * 2017-08-31 2017-11-17 银丰生物工程集团有限公司 Magnetic bead is coupled method and the application of the amplification in vitro NK cells of a variety of stimulates the proteins
CN108192824A (en) * 2018-01-19 2018-06-22 深圳光彩生命工程技术有限公司 A kind of Double layer culture device, the system and method for NK cells
CN108251376A (en) * 2017-12-21 2018-07-06 王文举 Artificial antigen presenting cell and its construction method and the application in the amplification of Chimeric antigen receptor T cell
CN108300693A (en) * 2018-01-25 2018-07-20 河北省健海生物芯片技术有限责任公司 A kind of natural killer cells amplification in vitro method
WO2018182511A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CN109486758A (en) * 2018-12-28 2019-03-19 青岛麦迪赛斯生物科技有限公司 A kind of external efficient amplification reagent of peripheral blood NK cell and operating instruction
US10428305B2 (en) 2014-05-15 2019-10-01 National University Of Singapore Modified natural killer cells that express IL15 and uses thereof
CN110669871A (en) * 2019-10-17 2020-01-10 河北森朗生物科技有限公司 Method for measuring transduction titer of lentivirus
CN110684730A (en) * 2019-10-11 2020-01-14 山东德升生物工程有限公司 Preparation method for efficiently amplifying NK cells by using trophoblasts
CN110951694A (en) * 2019-12-30 2020-04-03 北京鼎成肽源生物技术有限公司 Preparation method of autologous trophoblast and culture method of SNK cells
CN111304255A (en) * 2020-02-21 2020-06-19 秦皇岛中邦干细胞医学科技有限公司 Trophoblast, preparation method thereof and application thereof in efficiently amplifying NK cells
CN111548994A (en) * 2020-04-24 2020-08-18 广东华夏健康生命科学有限公司 Cell culture medium and method for culturing NK cells by using same
CN113416700A (en) * 2021-07-09 2021-09-21 天晴干细胞股份有限公司 Efficient factor-secreting NK cell amplification method and application thereof
US11141436B2 (en) 2019-03-05 2021-10-12 Nkarta, Inc. Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
US11365236B2 (en) 2017-03-27 2022-06-21 Nkarta, Inc. Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
CN114874985A (en) * 2022-06-16 2022-08-09 杭州中赢生物医疗科技有限公司 High-purity high-efficiency amplification method of NK cells
CN115461451A (en) * 2020-06-09 2022-12-09 社会福祉法人三星生命公益财团 Genetically engineered cell lines for activating and amplifying NK cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103243072A (en) * 2013-05-09 2013-08-14 浙江中赢方舟生物工程股份有限公司 Method for amplifying and activating lymphocyte cells by CD 8 alpha-interleukin 21 fragment-CD137 complex

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103243072A (en) * 2013-05-09 2013-08-14 浙江中赢方舟生物工程股份有限公司 Method for amplifying and activating lymphocyte cells by CD 8 alpha-interleukin 21 fragment-CD137 complex

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEI CHEN ET AL.: "Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRz Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma", 《MED SCI MONIT》 *
李亚芬: "改良型人NK细胞体外扩增技术建立及CAR-NK细胞治疗技术初步研究", 《中国优秀硕士学位论文全文数据库》 *
黄庆生等: "人NK细胞体外高效扩增的实验研究", 《细胞与分子免疫学杂志》 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10428305B2 (en) 2014-05-15 2019-10-01 National University Of Singapore Modified natural killer cells that express IL15 and uses thereof
US11560548B2 (en) 2014-05-15 2023-01-24 National University Of Singapore Immune cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof
US10774311B2 (en) 2014-05-15 2020-09-15 National University Of Singapore Natural killer cells modified to express membrane-bound interleukin 15 and uses thereof
CN110494557A (en) * 2017-03-27 2019-11-22 新加坡国立大学 For expanding the stimulation cell line with Activated NK Cells in vitro
WO2018182511A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
US11365236B2 (en) 2017-03-27 2022-06-21 Nkarta, Inc. Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
JP7270253B2 (en) 2017-03-27 2023-05-10 ナショナル ユニヴァーシティ オブ シンガポール Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
US11896616B2 (en) 2017-03-27 2024-02-13 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
JP2020516238A (en) * 2017-03-27 2020-06-11 ナショナル ユニヴァーシティ オブ シンガポール Stimulator cell line for ex vivo expansion and activation of natural killer cells
CN107354133A (en) * 2017-08-31 2017-11-17 银丰生物工程集团有限公司 Magnetic bead is coupled method and the application of the amplification in vitro NK cells of a variety of stimulates the proteins
CN108251376B (en) * 2017-12-21 2021-08-13 王文举 Artificial antigen presenting cell, construction method thereof and application thereof in chimeric antigen receptor T cell amplification
CN108251376A (en) * 2017-12-21 2018-07-06 王文举 Artificial antigen presenting cell and its construction method and the application in the amplification of Chimeric antigen receptor T cell
CN108192824A (en) * 2018-01-19 2018-06-22 深圳光彩生命工程技术有限公司 A kind of Double layer culture device, the system and method for NK cells
CN108300693A (en) * 2018-01-25 2018-07-20 河北省健海生物芯片技术有限责任公司 A kind of natural killer cells amplification in vitro method
CN109486758A (en) * 2018-12-28 2019-03-19 青岛麦迪赛斯生物科技有限公司 A kind of external efficient amplification reagent of peripheral blood NK cell and operating instruction
US11253547B2 (en) 2019-03-05 2022-02-22 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
US11141436B2 (en) 2019-03-05 2021-10-12 Nkarta, Inc. Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
US11154575B2 (en) 2019-03-05 2021-10-26 Nkarta, Inc. Cancer immunotherapy using CD19-directed chimeric antigen receptors
CN110684730A (en) * 2019-10-11 2020-01-14 山东德升生物工程有限公司 Preparation method for efficiently amplifying NK cells by using trophoblasts
CN110669871A (en) * 2019-10-17 2020-01-10 河北森朗生物科技有限公司 Method for measuring transduction titer of lentivirus
CN110951694A (en) * 2019-12-30 2020-04-03 北京鼎成肽源生物技术有限公司 Preparation method of autologous trophoblast and culture method of SNK cells
CN111304255B (en) * 2020-02-21 2023-06-09 中邦干细胞科技有限公司 Nourishing cell, preparation method thereof and application of nourishing cell in efficient amplification of NK cells
CN111304255A (en) * 2020-02-21 2020-06-19 秦皇岛中邦干细胞医学科技有限公司 Trophoblast, preparation method thereof and application thereof in efficiently amplifying NK cells
CN111548994B (en) * 2020-04-24 2021-05-25 广东华夏健康生命科学有限公司 Cell culture medium and method for culturing NK cells by using same
CN111548994A (en) * 2020-04-24 2020-08-18 广东华夏健康生命科学有限公司 Cell culture medium and method for culturing NK cells by using same
CN115461451A (en) * 2020-06-09 2022-12-09 社会福祉法人三星生命公益财团 Genetically engineered cell lines for activating and amplifying NK cells and uses thereof
CN113416700A (en) * 2021-07-09 2021-09-21 天晴干细胞股份有限公司 Efficient factor-secreting NK cell amplification method and application thereof
CN114874985A (en) * 2022-06-16 2022-08-09 杭州中赢生物医疗科技有限公司 High-purity high-efficiency amplification method of NK cells

Similar Documents

Publication Publication Date Title
CN105985931A (en) NK cell in-vitro amplification composition and NK cell amplification method
AU2006328943B2 (en) Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
US7951365B2 (en) Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
CN102597222A (en) Method for proliferation of antigen-specific T cells
CN101258238A (en) Method for activation treatment of antigen-presenting cell
CN105087488A (en) Preparation method and application of DC-CIK cell induced by tumor antigen
CN101481677A (en) Method for maturing dendritic cell by in vitro stimulation
CN105316287A (en) Method for long-term storage and resuscitation culture of adult peripheral blood mononuclear cell
CN107384949A (en) The constant natural killer T cells of expression targeting GPC3 Chimeric antigen receptors（iNKT）And its prepare and apply
CN109055430A (en) A kind of preparation method for co-expressing IL18 and CCL19 albumen and targeting MUC1 gene C AR-T cell
US20230346935A1 (en) Tumor complex antigen, multivalent dendritic cell (dc) vaccine, and use thereof
CN102719402B (en) Preparation method of HLA-A0201-restricted anti-HPV (human papillomavirus) antigen-specific CTL
CN104894072A (en) Preparation method and application of autologous natural killer cell proliferation
CN110016465A (en) A kind of immunocyte drug comprising B cell and the double identity T cells of tumour
CN105969731B (en) A method of High Fragmentation activity til cell is largely prepared using pernicious Pleural effusions
CN103013914A (en) Method for in-vitro culture of killer T cells
CN103097398B (en) Immunogenic peptide and comprise the composition for preventing or treat HPV relative disease of this peptide
CN102219835B (en) Long peptide based on HCA587 antigen and its application in preparing antitumor drugs
CN109957543A (en) Utilize the method for Cord blood massive amplification Cord Blood Natural Killer Cells: Impact
TWI458485B (en) Application of cytotoxic dendritic cells for manufacturing medication and comprising pharmaceutical composition
CN117230007A (en) CTL (cytotoxic T lymphocyte) cell based on DC Line induction and preparation method thereof
CN105031631A (en) Preparation method and application of HLA-A0201-restrictive anti-Sox2 specific CTL
CN105219728A (en) A kind of for activating the immunoreactive test kit of Breast Cancer-Specific
CN103710308B (en) Muramyl dipeptide is utilized to induce the method for DC-CIK
CN105219727A (en) A kind of test kit for activating colorectal cancer specific immune response

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination